SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

IVVD

Invivyd
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS beat and revenue growth are overshadowed by the revenue miss vs consensus and widening losses. The key catalyst is the DECLARATION top-line data in Q3 2026, monitor for enrollment completion and event accumulation updates. The ATM raise and cash runway suggest no near-term financing urgency, but the 158% share count dilution over the past year is a structural overhang.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.16
T+0 close · May 14, 2026 · via day close
Latest settled
−41.97%
T+60 · $0.6731
Vs SPY
−45.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $1.16entry
  2. T+1 · 6mo ago +4.31%α +5.54% · $1.21
  3. T+5 · 6mo ago −4.31%α −3.59% · $1.11
  4. T+20 · 5mo ago −33.62%α −32.76% · $0.7700
  5. T+60 · 3mo ago −41.97%α −45.56% · $0.6731
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Invivyd reported Q1 2026 PEMGARDA revenue of $13.7M (+22% YoY), beating consensus estimates on both revenue ($13.7M vs $18.1M expected) and EPS (-$0.04 vs -$0.08 expected). The company highlighted continued in vitro neutralizing activity against the BA.3.2.2 variant, IDMC recommendation to reduce post-dose monitoring time for VYD2311, and a strong cash position of $184.2M providing runway through the DECLARATION data readout in Q3 2026. However, net loss widened to $41.4M from $16.3M a year ago due to increased R&D spending on the DECLARATION trial, and the company raised ~$20M via ATM in April.

Key Financial Metrics

EPS
−$0.04
est −$0.08 · +50.0%
Revenue
$13.7M
est $18.1M · -24.1% · +21.6% YoY
Rating
in line

Key Facts

  • Q1 2026 PEMGARDA net product revenue $13.7M, up 22% from $11.3M in Q1 2025
  • EPS -$0.04 beat consensus of -$0.08 (50% beat)
  • Revenue $13.7M missed consensus of $18.1M (24% miss)
  • Net loss widened to $41.4M from $16.3M YoY, driven by $30.7M R&D (vs $10.6M)
  • Cash and equivalents $184.2M as of March 31, 2026; additional ~$20M raised via ATM in April 2026
  • IDMC recommended reduction of VYD2311 post-dose monitoring from 2 hours to 30 minutes
  • DECLARATION trial upsized by ~500 subjects; top-line data expected Q3 2026 (shifted from mid-2026)
  • Measles mAb candidate VMS063 advancing toward IND readiness in late 2026
  • Weighted-average shares outstanding 309.7M (basic/diluted), up 158% YoY from 119.9M

Financial Impact

Revenue beat consensus by 24% on a dollar basis ($13.7M vs $18.1M), but EPS beat was on a small absolute base. Net loss widened significantly. Cash burn rate increased.

revenuenet losscash positionR&D expense

Risk Factors

  • Revenue miss vs consensus of $18.1M despite 22% YoY growth, top-line expectations may have been too high
  • Net loss more than doubled to $41.4M with R&D spending tripling; cash burn rate is accelerating
  • DECLARATION trial upsized by ~500 subjects, pushing data readout to Q3 2026, adds execution risk and delays catalyst
  • 158% YoY dilution in weighted-average shares outstanding pressures per-share metrics
  • PEMGARDA EUA is contingent on variant susceptibility; future variants could reduce its effectiveness

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294770

Track record

19 reports on IVVD

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
  2. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
  3. Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
  5. Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
  6. Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
  7. Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
  8. Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
  10. Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026